Literature DB >> 2409802

The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.

D B Chandler, G Rozakis, E de Juan, R Machemer.   

Abstract

Animal models of proliferative vitreoretinopathy in which the intact vitreous body is injected with large numbers of fibroblasts do not resemble the human situation. Using a refined rabbit model of proliferative vitreoretinopathy in which the vitreous is compressed and partially detached from the retinal surface and small amounts of tissue-cultured homologous fibroblasts (25,000) are scattered over the vascularized part of the retina, we reevaluated the effect of intravitreally injected triamcinolone acetonide. We found that 2 mg of the corticosteroid reduced the incidence of retinal detachments from 90% to 56%. The effect was less than in previous models with intact vitreous. Large doses of the corticosteroid had no additional effect on the reduction of retinal detachments, indicating an optimal dosage of 2 mg. The effect of the corticosteroid on neovascularization was considerable; with 8 mg it could almost be prevented (reduction from 74% to 8%).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409802     DOI: 10.1016/s0002-9394(14)76037-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  20 in total

1.  Intravitreal triamcinolone in recurrence of choroidal neovascularisation.

Authors:  P L Penfold
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

2.  Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications.

Authors:  G W Blankenship
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

3.  The effect of X-ray irradiation on human retinal pigment epithelial cell proliferation.

Authors:  T Ohuchi; S Kuriyama; N Yoshimura; Y Honda; M Hiraoka; M Abe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

4.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

5.  Influence of different purification techniques on triamcinolone yield and particle size spectrum.

Authors:  Peter Szurman; Radoslaw Kaczmarek; Gesine B Jaissle; Salvatore Grisanti; Matthias Lüke; Martin S Spitzer; Peter-Edgar Heide; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

6.  The lack of an effect of intraocular steroids on irradiated fibroblasts in experimental proliferative vitreoretinopathy.

Authors:  D B Chandler; T Hida; G Rozakis; V S Forbes; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

Review 7.  [Modern pharmacotherapy of age-related macular degeneration].

Authors:  F G Holz; H M Helb; A Bindewald-Wittich; H P N Scholl
Journal:  Internist (Berl)       Date:  2006-02       Impact factor: 0.743

8.  Treatment of neovascular age-related macular degeneration: Current therapies.

Authors:  Albert J Augustin; Stefan Scholl; Janna Kirchhof
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.

Authors:  J A Cardillo; M E Farah; J Mitre; P H Morales; R A Costa; L A S Melo; B Kuppermann; R Jorge; P Ashton
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

10.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.